Pseudocystic foveal cavitation in tamoxifen retinopathy.

[1]  B. J. Klevering,et al.  Multimodal imaging of the macula in hereditary and acquired lack of macular pigment , 2014, Acta ophthalmologica.

[2]  S. Barni,et al.  Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials , 2013, Breast Cancer Research and Treatment.

[3]  I. Georgalas,et al.  Large bilateral foveal cysts in the inner retina of a patient treated with tamoxifen, diagnosed with Fourier-domain optical coherence tomography , 2013, Clinical ophthalmology.

[4]  A. Nair,et al.  The eyes have it! Tamoxifen maculopathy revisited: a case report. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[5]  David Williams,et al.  Retinal crystals in type 2 idiopathic macular telangiectasia. , 2010, Ophthalmology (Rochester, Minn.).

[6]  R. Guymer,et al.  Perifoveal müller cell depletion in a case of macular telangiectasia type 2. , 2010, Ophthalmology.

[7]  H. Chung,et al.  Estrogen Antagonist and Development of Macular Hole , 2010, Korean journal of ophthalmology : KJO.

[8]  Nirmala Srikantia,et al.  Crystalline maculopathy: a rare complication of tamoxifen therapy. , 2010, Journal of cancer research and therapeutics.

[9]  S. Ahn,et al.  Early Detection of Tamoxifen-induced Maculopathy in Patients With Low Cumulative Doses of Tamoxifen. , 2010, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.

[10]  J. Sallum,et al.  Retinal function in patients treated with tamoxifen , 2010, Documenta Ophthalmologica.

[11]  R. Zawadzki,et al.  Microcystoid maculopathy associated with tamoxifen use diagnosed by high-resolution fourier-domain optical coherence tomography. , 2009, Retinal cases & brief reports.

[12]  Julie Brown,et al.  Clomiphene and anti-oestrogens for ovulation induction in PCOS. , 2009, The Cochrane database of systematic reviews.

[13]  H. Scholl,et al.  ABNORMAL MACULAR PIGMENT DISTRIBUTION IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA , 2008, Retina.

[14]  P. Bernstein,et al.  Diagnostic & therapeutic challenges. Tamoxifen toxicity. , 2007, Retina.

[15]  D. Sarraf,et al.  Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. , 2007, American journal of ophthalmology.

[16]  A. Berezovsky,et al.  Multifocal Electroretinography, Color Discrimination and Ocular Toxicity in Tamoxifen Use , 2007, Current eye research.

[17]  Peter Wiedemann,et al.  Müller cells in the healthy and diseased retina , 2006, Progress in Retinal and Eye Research.

[18]  Mauget-Faÿsse Martine,et al.  Optical coherence tomography in tamoxifen retinopathy , 2006, Breast Cancer Research and Treatment.

[19]  A. Eisner,et al.  Small Optic Cup Sizes Among Women Using Tamoxifen: Assessment with Scanning Laser Ophthalmoscopy , 2006, Current eye research.

[20]  R. Bourke,et al.  Tamoxifen therapy conveys increased risk of developing a macular hole , 2006, International Ophthalmology.

[21]  J. Sahel,et al.  Optical coherence tomography findings in tamoxifen retinopathy. , 2005, American journal of ophthalmology.

[22]  Wei Zhang,et al.  Agents with Selective Estrogen Receptor (ER) Modulator Activity Induce Apoptosis In vitro and In vivo in ER-Negative Glioma Cells , 2004, Cancer Research.

[23]  K. Holli,et al.  Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. , 2003, Acta ophthalmologica Scandinavica.

[24]  L. Salminen,et al.  Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells. , 2002, Pharmacology & toxicology.

[25]  C. Flaxel,et al.  Intraocular penetration of tamoxifen. , 2000, Ophthalmology.

[26]  M. Seoud,et al.  Ocular toxicity in low-dose tamoxifen: A prospective study , 1999, Eye.

[27]  G. Savini,et al.  Tamoxifen retinopathy: does it really exist? , 1998, Graefe's Archive for Clinical and Experimental Ophthalmology.

[28]  L. Mastronardi,et al.  Tamoxifen as a potential treatment of glioma. , 1998, Anti-cancer drugs.

[29]  C. Redmond,et al.  Long-term tamoxifen citrate use and potential ocular toxicity. , 1998, American journal of ophthalmology.

[30]  Helen K. Li,et al.  Retinal changes associated with tamoxifen treatment for breast cancer , 1997, Eye.

[31]  M. Gorin,et al.  Tamoxifen-associated eye disease. A review. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Leys,et al.  Screening for Tamoxifen Ocular Toxicity: A Prospective Study , 1995, European journal of ophthalmology.

[33]  R. Enzenauer,et al.  Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. , 1994, American journal of ophthalmology.

[34]  N. Pavlidis,et al.  Clear evidence that long‐term, low‐dose tamoxifen treatment can induce ocular toxicity a prospective study of 63 patients , 1992, Cancer.

[35]  H. Sigurdsson,et al.  A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. , 1989, European journal of cancer & clinical oncology.

[36]  T. Vinding,et al.  RETINOPATHY CAUSED BY TREATMENT WITH TAMOXIFEN IN LOW DOSAGE , 1983, Acta ophthalmologica.

[37]  M. Kaiser-Kupfer,et al.  1. Tamoxifen Retinopathy: A Clinicopathologic Report , 1981 .

[38]  P. Mills,et al.  Ocular assessment of patients treated with tamoxifen. , 1979, Cancer treatment reports.

[39]  The Reflexes of the Fundus Oculi , 1940 .